SCHEMBL3470360

SCHEMBL3470360

Cc1cc(F)ccc1C1CCN(C(=O)c2cccc(N3CCN(C)CC3)n2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 1/20 0.48
FAAH O00519 1/20 0.43
OPRL1 P41146 3/20 0.42
CNR2 P34972 1/20 0.42
SCD5 Q86SK9 3/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
OPRM1 P35372 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
MAPK1 P28482 1/20 0.40
HRH4 Q9H3N8 2/20 0.39
KCNH2 Q12809 1/20 0.39
PRKCQ Q04759 1/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3469936 0.93 HSD17B14 (0.47) HSD17B14FAAHCNR2SCD5HTR3E
SCHEMBL4305205 0.91 HSD17B14 (0.51) HSD17B14FAAHCNR2SCD5HTR3E
SCHEMBL3466796 0.90 HSD17B14 (0.53) HSD17B14FAAHCNR2SCD5HTR3E
SCHEMBL3467772 0.85 HSD17B14 (0.48) HSD17B14CNR2HTR3EHTR3BHTR3A
SCHEMBL3467150 0.85 HSD17B14 (0.50) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL3466779 0.84 HSD17B14 (0.49) HSD17B14FAAHHTR3EHTR3BHTR3A
SCHEMBL3466177 0.84 HSD17B14 (0.49) HSD17B14FAAHHTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL4297856 0.83 HSD17B14 (0.48) HSD17B14FAAHHTR3EHTR3BHTR3A
SCHEMBL3469979 0.82 USP2 (0.52) HSD17B14FAAHHTR3EHTR3BHTR3A
SCHEMBL3468410 0.82 OPRL1 (0.44) OPRL1CNR2SCD5OPRM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265600-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS Pfizer Inc. (US) 2010-12-29 EP claimed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO claimed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US claimed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885FAAH 217/4885OPRL1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.